Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study
ONCOLOGY · 12.03.2026 · 40 (2) · 106
DOI: 10.46883/2026.25921066 ↗Kurz gefasst
Fachartikel in der Zeitschrift ONCOLOGY, online erschienen am 26.03.2026. Verfasst von Shiny Chih-Hsuan Wu und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Doxorubicin, Sarcoma, Antibiotics, Antineoplastic. Die Arbeit nennt 22 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Soft tissue sarcomas (STS) are rare but aggressive tumors. Although surgery and radiotherapy are standard treatments for localized STS, the role of adjuvant chemotherapy, particularly doxorubicin, in high-grade STS is debated.
Methods
This retrospective study evaluated the effectiveness of single-agent doxorubicin in resectable grade 2 and 3 STS, with a focus on oncologic outcomes. Adults with biopsy-confirmed STS of the extremities or trunk, treated at a tertiary center in Taiwan between January 2004 and March 2020, were included. Primary outcomes were distant metastasis–free survival (DMFS) and overall survival (OS).
Results
The study enrolled 62 patients in either the single-agent doxorubicin adjuvant chemotherapy group (n = 8) or the observation-only group (n = 54). The mean age was 45.4 years in the adjuvant chemotherapy group and 58.2 years in the observation-only group. The 3-year OS was 100% in the chemotherapy group and 60% in the observation group (log-rank P = .064). The 3-year DMFS rate was 75% in the chemotherapy group and 45% in the observation group (log-rank P = .078).
Conclusion
In resectable, high-grade STS of 8 cm or more, single-agent doxorubicin as adjuvant chemotherapy showed a trend toward improved OS and DMFS compared with observation alone; however, statistical significance was not reached. Keywords: Adjuvant chemotherapy, distant metastasis–free survival, doxorubicin, overall survival, soft tissue sarcomas
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Chih-Hsuan Wu, S., Wu, Y. Y., Liau, C. T., Chang, C. H., Huang, S. C., Shih, H. N., & Chen, C. C. (2026). Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study. ONCOLOGY, 40(2), 106. https://doi.org/10.46883/2026.25921066
Vancouver
Chih-Hsuan Wu S, Wu YY, Liau CT, Chang CH, Huang SC, Shih HN, et al. Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study. ONCOLOGY. 2026;40(2):106. doi:10.46883/2026.25921066
BibTeX
@article{ChihHsuanWu2026,
author = {Chih-Hsuan Wu, Shiny and Wu, Yao-Yu and Liau, Chi-Ting and Chang, Chih-Hsiang and Huang, Shih-Chiang and Shih, Hsin-Nung and Chen, Chun-Chieh},
title = {Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study},
journal = {ONCOLOGY},
year = {2026},
volume = {40},
number = {2},
pages = {106},
doi = {10.46883/2026.25921066}
}
EUVIMED